Oct 21 (Reuters) - Metacrine, Inc. MTCR.O :
* METACRINE REPORTS INTERIM RESULTS FOR MET642 PHASE 2A TRIAL IN PATIENTS WITH NASH AND ANNOUNCES A STRATEGIC RE-PRIORITIZATION OF ITS CLINICAL DEVELOPMENT PROGRAMS
* METACRINE - PRIORITIZING CLINICAL DEVELOPMENT EFFORT AND RESOURCES TO ADVANCE MET642 INTO A PHASE 2 TRIAL IN IBD IN FIRST HALF OF 2022
* METACRINE, INC. - EXPECTS INDEPENDENT REVIEW OF MET642 TO BE COMPLETED BEFORE END OF 2021
* METACRINE, INC. - CONDUCTING AN INDEPENDENT REVIEW OF PRELIMINARY FINDINGS FROM A RECENTLY COMPLETED NINE-MONTH ANIMAL TOXICOLOGY STUDY FOR MET642
* METACRINE, INC. - TO HALT FUTURE DEVELOPMENT OF FXR PROGRAM IN NASH
* METACRINE, INC. - DECISION WAS INFLUENCED IN PART BY A POTENTIAL DELAY IN CONFIRMING APPROPRIATE SAFETY MARGINS IN LONG-TERM TOXICOLOGY WORK
* METACRINE, INC. - MET642 WAS GENERALLY WELL-TOLERATED, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS
Source text for Eikon: Further company coverage: